MedTrace Logo

The STRETCH Study: Distensibility on Endothelial-Dependent Vasoreactivity in Subjects With Systolic Hypertension

NCT00302250 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2006-03-22

No results posted yet for this study

Summary

The primary objective of the double-blind segment is to compare effects of alagebrium vs placebo on change from baseline in endothelial function, as assessed by flow-mediated vasodilation (FMD).

Conditions

Interventions

DRUG

ALT-711 (alagebrium chloride)

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Heart and Lung Institute

    collaborator OTHER

  • Synvista Therapeutics, Inc

    lead INDUSTRY

Principal Investigators

  • Susan Zieman, MD, PhD · Johns Hopkins University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Completion
2006-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00302250 on ClinicalTrials.gov